Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial

Detalles Bibliográficos
Autores principales: Wu, Jashin J., Spelman, Lynda, Tan, Jerry L., Etoh, Takafumi, Zhang, Haixin, Shumel, Brad, Rossi, Ana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019003/
https://www.ncbi.nlm.nih.gov/pubmed/33511576
http://dx.doi.org/10.1007/s13555-021-00487-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019003/
https://www.ncbi.nlm.nih.gov/pubmed/33511576
http://dx.doi.org/10.1007/s13555-021-00487-y

Ejemplares similares